AVANOS MEDICAL INC (AVNS) Stock Fundamental Analysis

NYSE:AVNS • US05350V1061

13.74 USD
-0.24 (-1.72%)
Last: Mar 3, 2026, 12:10 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to AVNS. AVNS was compared to 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of AVNS get a neutral evaluation. Nothing too spectacular is happening here. AVNS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • AVNS had positive earnings in the past year.
  • In the past year AVNS had a positive cash flow from operations.
  • In multiple years AVNS reported negative net income over the last 5 years.
  • In the past 5 years AVNS always reported a positive cash flow from operatings.
AVNS Yearly Net Income VS EBIT VS OCF VS FCFAVNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • With a decent Return On Assets value of -6.79%, AVNS is doing good in the industry, outperforming 65.76% of the companies in the same industry.
  • The Return On Equity of AVNS (-9.37%) is better than 68.48% of its industry peers.
  • AVNS's Return On Invested Capital of 1.47% is fine compared to the rest of the industry. AVNS outperforms 67.93% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AVNS is significantly below the industry average of 8.75%.
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROIC 1.47%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
AVNS Yearly ROA, ROE, ROICAVNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • AVNS has a better Operating Margin (2.41%) than 67.93% of its industry peers.
  • In the last couple of years the Operating Margin of AVNS has declined.
  • AVNS has a Gross Margin (50.47%) which is comparable to the rest of the industry.
  • AVNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 2.41%
PM (TTM) N/A
GM 50.47%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
AVNS Yearly Profit, Operating, Gross MarginsAVNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • AVNS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for AVNS has been increased compared to 1 year ago.
  • The number of shares outstanding for AVNS has been reduced compared to 5 years ago.
  • Compared to 1 year ago, AVNS has an improved debt to assets ratio.
AVNS Yearly Shares OutstandingAVNS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
AVNS Yearly Total Debt VS Total AssetsAVNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 1.22, we must say that AVNS is in the distress zone and has some risk of bankruptcy.
  • AVNS has a Altman-Z score (1.22) which is comparable to the rest of the industry.
  • AVNS has a debt to FCF ratio of 2.33. This is a good value and a sign of high solvency as AVNS would need 2.33 years to pay back of all of its debts.
  • AVNS has a Debt to FCF ratio of 2.33. This is amongst the best in the industry. AVNS outperforms 86.41% of its industry peers.
  • AVNS has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • AVNS has a Debt to Equity ratio of 0.12. This is in the better half of the industry: AVNS outperforms 63.59% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Altman-Z 1.22
ROIC/WACC0.15
WACC9.81%
AVNS Yearly LT Debt VS Equity VS FCFAVNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • AVNS has a Current Ratio of 2.15. This indicates that AVNS is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of AVNS (2.15) is comparable to the rest of the industry.
  • A Quick Ratio of 1.26 indicates that AVNS should not have too much problems paying its short term obligations.
  • AVNS's Quick ratio of 1.26 is on the low side compared to the rest of the industry. AVNS is outperformed by 65.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.26
AVNS Yearly Current Assets VS Current LiabilitesAVNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AVNS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.40%.
  • AVNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.80% yearly.
  • AVNS shows a small growth in Revenue. In the last year, the Revenue has grown by 1.95%.
  • The Revenue has been decreasing by -0.38% on average over the past years.
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%

3.2 Future

  • AVNS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.51% yearly.
  • Based on estimates for the next years, AVNS will show a small growth in Revenue. The Revenue will grow by 3.19% on average per year.
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
AVNS Yearly Revenue VS EstimatesAVNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
AVNS Yearly EPS VS EstimatesAVNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 14.62 indicates a correct valuation of AVNS.
  • Based on the Price/Earnings ratio, AVNS is valued cheaply inside the industry as 88.59% of the companies are valued more expensively.
  • AVNS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.13.
  • A Price/Forward Earnings ratio of 13.46 indicates a correct valuation of AVNS.
  • Based on the Price/Forward Earnings ratio, AVNS is valued cheaply inside the industry as 90.22% of the companies are valued more expensively.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.11, AVNS is valued rather cheaply.
Industry RankSector Rank
PE 14.62
Fwd PE 13.46
AVNS Price Earnings VS Forward Price EarningsAVNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AVNS indicates a rather cheap valuation: AVNS is cheaper than 88.04% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, AVNS is valued cheaply inside the industry as 95.65% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 14.82
EV/EBITDA 11.84
AVNS Per share dataAVNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AVNS's earnings are expected to grow with 16.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.7
PEG (5Y)3.84
EPS Next 2Y16.51%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AVNS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVANOS MEDICAL INC

NYSE:AVNS (3/3/2026, 12:10:46 PM)

13.74

-0.24 (-1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners96.89%
Inst Owner Change27.64%
Ins Owners2.95%
Ins Owner Change-0.82%
Market Cap638.91M
Revenue(TTM)701.20M
Net Income(TTM)-72.90M
Analysts43.33
Price TargetN/A
Short Float %6.62%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.19%
Min EPS beat(2)14.64%
Max EPS beat(2)79.74%
EPS beat(4)4
Avg EPS beat(4)36.78%
Min EPS beat(4)11.11%
Max EPS beat(4)79.74%
EPS beat(8)5
Avg EPS beat(8)16.95%
EPS beat(12)7
Avg EPS beat(12)15.54%
EPS beat(16)10
Avg EPS beat(16)13.47%
Revenue beat(2)2
Avg Revenue beat(2)3.74%
Min Revenue beat(2)1.52%
Max Revenue beat(2)5.97%
Revenue beat(4)4
Avg Revenue beat(4)3.17%
Min Revenue beat(4)1.52%
Max Revenue beat(4)5.97%
Revenue beat(8)4
Avg Revenue beat(8)0.74%
Revenue beat(12)4
Avg Revenue beat(12)-0.83%
Revenue beat(16)4
Avg Revenue beat(16)-4.39%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.91%
EPS NQ rev (3m)3.91%
EPS NY rev (1m)0%
EPS NY rev (3m)5.2%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.29%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.65%
Valuation
Industry RankSector Rank
PE 14.62
Fwd PE 13.46
P/S 0.91
P/FCF 14.82
P/OCF 8.55
P/B 0.82
P/tB 2.41
EV/EBITDA 11.84
EPS(TTM)0.94
EY6.84%
EPS(NY)1.02
Fwd EY7.43%
FCF(TTM)0.93
FCFY6.75%
OCF(TTM)1.61
OCFY11.69%
SpS15.08
BVpS16.74
TBVpS5.71
PEG (NY)1.7
PEG (5Y)3.84
Graham Number18.81
Profitability
Industry RankSector Rank
ROA -6.79%
ROE -9.37%
ROCE 1.86%
ROIC 1.47%
ROICexc 1.63%
ROICexgc 4.36%
OM 2.41%
PM (TTM) N/A
GM 50.47%
FCFM 6.15%
ROA(3y)-14.8%
ROA(5y)-8.25%
ROE(3y)-20.56%
ROE(5y)-11.47%
ROIC(3y)1.82%
ROIC(5y)2.02%
ROICexc(3y)2.02%
ROICexc(5y)2.23%
ROICexgc(3y)5.81%
ROICexgc(5y)7.12%
ROCE(3y)2.3%
ROCE(5y)2.56%
ROICexgc growth 3Y-33.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-26.31%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-0.68%
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 2.33
Debt/EBITDA 1.62
Cap/Depr 81.23%
Cap/Sales 4.51%
Interest Coverage 2.6
Cash Conversion 133.87%
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.26
Altman-Z 1.22
F-Score6
WACC9.81%
ROIC/WACC0.15
Cap/Depr(3y)52.99%
Cap/Depr(5y)50.85%
Cap/Sales(3y)3.25%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.4%
EPS 3Y-17.1%
EPS 5Y3.8%
EPS Q2Q%-30.95%
EPS Next Y8.62%
EPS Next 2Y16.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)1.95%
Revenue growth 3Y-5.08%
Revenue growth 5Y-0.38%
Sales Q2Q%0.72%
Revenue Next Year2.16%
Revenue Next 2Y3.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-62.19%
EBIT growth 3Y-39.42%
EBIT growth 5YN/A
EBIT Next Year165.31%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.01%
FCF growth 3Y-15.57%
FCF growth 5YN/A
OCF growth 1Y-25.82%
OCF growth 3Y-6.33%
OCF growth 5YN/A

AVANOS MEDICAL INC / AVNS FAQ

Can you provide the ChartMill fundamental rating for AVANOS MEDICAL INC?

ChartMill assigns a fundamental rating of 4 / 10 to AVNS.


What is the valuation status for AVNS stock?

ChartMill assigns a valuation rating of 6 / 10 to AVANOS MEDICAL INC (AVNS). This can be considered as Fairly Valued.


Can you provide the profitability details for AVANOS MEDICAL INC?

AVANOS MEDICAL INC (AVNS) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for AVNS stock?

The Earnings per Share (EPS) of AVANOS MEDICAL INC (AVNS) is expected to grow by 8.62% in the next year.